Harmony Biosciences Holdings Inc Dossier - Source-backed chat

Harmony Biosciences Holdings Inc

HRMYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.95

Intrinsic Value $77.34median of 6 methods · middle span $43-$311based on filings through 30 Jun 2026

Market Price $39.57Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 95% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+95%)

Data confidence Sign in to view data confidence

Market Cap $2.3B

Enterprise Value $1.9B

Shares Outstanding 58.8M diluted

Moat Rating Wide

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Harmony Biosciences is a highly profitable, self-funding commercial-stage biopharmaceutical company specializing in rare neurological disorders. The investment thesis is anchored by its flagship product, WAKIX (pitolisant), which is on track to achieve blockbuster status in 2026 with guided net product revenues of $1.0 billion to $1.04 billion. Despite near-term seasonal market access headwinds and an earnings miss in Q1 2026 due to strategic licensing fees, the company's underlying demand remains robust. Harmony is actively mitigating its single-product concentration risk by advancing next-generation formulations (Pitolisant GR and Pitolisant HD) to extend its franchise lifecycle into the 2040s, alongside expanding into broader CNS indications (e.g., orexin-2 receptor agonist BP-205). Trading at a highly attractive forward P/E multiple relative to its growth profile, Harmony offers a compelling risk-reward opportunity.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$46.10

High · most bullish analyst$70.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$28.0015%

WAKIX sales growth slows below $1.0B due to intensifying competition from once-nightly sodium oxybates (e.g., Lumryz) and market access headwinds. Pitolisant GR faces regulatory delays or a complete response letter (CRL) from the FDA. Phase 3 trials for Pitolisant HD or PWS fail to meet primary endpoints, similar to the historical INTUNE study setback in idiopathic hypersomnia, leaving the company highly vulnerable to generic entry in 2030.

Base CaseCentral scenario

$46.1060%

Matches the consensus mean

WAKIX achieves blockbuster status in 2026, meeting guidance of $1.0B to $1.04B. Pitolisant GR is submitted in Q2 2026 and approved in Q1 2027, ensuring a smooth lifecycle transition. Phase 3 trials for Pitolisant HD progress on schedule for 2027 readouts. The company maintains solid profitability with temporary margin compression from strategic R&D investments, supported by its strong cash position of over $870 million.

Bull CaseUpside scenario

$62.0025%

WAKIX exceeds the high end of 2026 guidance ($1.04B+) driven by rapid pediatric adoption and strong commercial execution. Pitolisant GR receives FDA approval in early 2027 with a highly favorable label, successfully transitioning patients and securing the franchise into the 2040s. Topline Phase 3 data for Prader-Willi Syndrome in 2H 2026 is outstanding, securing pediatric exclusivity. The orexin-2 agonist (BP-205) Phase 1 data in mid-2026 demonstrates best-in-class PK properties, opening up multi-billion dollar CNS markets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

WAKIX is on track to achieve blockbuster status in 2026 with guided net product revenues of $1.0B to $1.04B.
Robust cash position of $870.5 million as of Q1 2026, providing significant financial flexibility for business development and pipeline expansion without dilutive financing.
Clear lifecycle extension strategy with Pitolisant GR (NDA in Q2 2026) and Pitolisant HD (PDUFA in 2028) designed to protect the franchise into the 2040s.
Attractive valuation, trading at a forward P/E of under 10x, representing a significant discount to specialty pharma peers.

Key Investment Risks

High product concentration risk, with virtually 100% of current commercial revenues derived from WAKIX.
Threat of generic competition starting in 2030 if next-generation formulations fail to successfully transition the patient base.
Clinical development risks, as highlighted by the historical refusal to file (RTF) letter for pitolisant in idiopathic hypersomnia in early 2025.
Intensifying competition in the narcolepsy market from established players like Jazz Pharmaceuticals and new entrants like Avadel Pharmaceuticals.

Thesis Invalidation Triggers

Failure to submit or secure FDA approval for Pitolisant GR, which would severely threaten the post-2030 franchise outlook.
A significant downward revision of the 2026 WAKIX revenue guidance of $1.0B to $1.04B.
Negative topline Phase 3 clinical data for pitolisant in Prader-Willi Syndrome in 2H 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.